Blueprint’s Ayvakit Mastocytosis Results Raise Commercial Uncertainty
The Phase III PIONEER study in indolent systemic mastocytosis met the primary endpoint, but the magnitude of benefit came up short of analysts’ expectations.
You may also be interested in...
Detailed data in indolent systemic mastocytosis show improvement across primary and key secondary endpoints, but analysts pointed to lower improvement on symptoms outside of those affecting the skin.
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.